Serum Institute of India to start production of Sputnik V from September

The Russian Direct Investment Fund informed that its deal with the Serum Institute of India envisages the annual production of more than 300 million doses of the COVID-19 vaccine in India starting in September. 

Created On: Jul 13, 2021 15:50 IST
Serum Institute of India to start production of Sputnik V from September
Serum Institute of India to start production of Sputnik V from September

India's top vaccine maker, Serum Institute of India (SII) will begin production of the Russian COVID-19 vaccine, Sputnik V from September 2021. This was informed by Kirill Dmitriev, CEO of the Russian Direct Investment Fund. 

Kirill Dmitriev also informed that some other manufactures are also ready to produce the vaccine in India. This will provide a major boost to India's vaccination drive. 

The Russian Direct Investment Fund informed that its deal with the Serum Institute of India envisages the annual production of more than 300 million doses of the COVID-19 vaccine in India starting in September. 

Significance

RDIF CEO Kirill Dmitriev said that the strategic partnership is a major step to substantially increase our production capabilities demonstrating a perfect example of joining forces and expertise to save lives both in India and around the world.

SII CEO Adar Poonawalla said that he is delighted to partner with RDIF to manufacture the Sputnik vaccine. He said that they hope to produce millions of doses in the coming months with trial batches starting in September. 

Poonawalla further said that with high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world. 

SII- RDIF Agreement: Key Highlights 

• The Serum Institute of India has already received the cell and vector samples from Russia's Gamaleya Centre as a part of the technology transfer process. 

• With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun in India.

• The Serum Institute of India (SII) had earlier sought regulatory approval to produce Russia's Sputnik V COVID-19 vaccine in India. 

• The Serum Institute of India is the world's largest vaccine maker and it is already making AstraZeneca PLC (AZN.L) and Novavax vaccines in India.

• The SII is currently working to ramp up the production of the Oxford-AstraZeneca vaccine, which is being sold in India under the brand name- Covishield.

RDIF Partners in India

• The Russian Direct Investment Fund (RDIF) had collaborated with many local Indian pharmaceutical players to locally manufacture Sputnik V doses including the Hyderabad-based Dr. Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech. 

• The Russian Direct Investment Fund had partnered with Dr. Reddy’s for conducting clinical trials of the vaccine in India in September 2020, a month after it received regulatory approval in Russia. 

• On May 24th, RDIF also announced a collaboration with Panacea Biotec, one of the leading Indian pharmaceutical producers, to launch the production of the Sputnik V coronavirus vaccine in India.

• India’s Morepen Laboratories and RDIF had also signed an agreement on cooperation in June 2021 for the production of the vaccine. The laboratory has started the production of the test batch of Russia’s Sputnik V vaccine at its own facility in Himachal Pradesh and the first batch will be shipped to the Gamaleya Center for quality check. 

• The Indian government expects to have around 156 million doses of the Sputnik V vaccine between August and December 2021. 

Background

India's Subject Expert Committee had in April 2021 approved Dr. Reddy's application for emergency use authorisation to Russia's Sputnik V COVID-19 vaccine, making it the third vaccine to receive emergency use approval in India after the two locally manufactured vaccines- Bharat Biotech's Covaxin and Oxford-Astrazeneca's Covishield.

Sputnik V is a two-dose vaccine which has been found to be 91.6% effective in preventing people from getting COVID-19. The vaccine's efficacy rate is higher than the two vaccines currently approved in India.

The vaccine has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology in collaboration with the Russian Direct Investment Fund (RDIF).

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

एग्जाम की तैयारी के लिए ऐप पर वीकली टेस्ट लें और दूसरों के साथ प्रतिस्पर्धा करें। डाउनलोड करें करेंट अफेयर्स ऐप

AndroidIOS

Related Stories

Comment (0)

Post Comment

6 + 2 =
Post
Disclaimer: Comments will be moderated by Jagranjosh editorial team. Comments that are abusive, personal, incendiary or irrelevant will not be published. Please use a genuine email ID and provide your name, to avoid rejection.

    Monthly Current Affairs PDF

    • Current Affairs PDF September 2021
    • Current Affairs PDF August 2021
    • Current Affairs PDF July 2021
    • Current Affairs PDF June 2021
    • Current Affairs PDF May 2021
    • Current Affairs PDF April 2021
    • Current Affairs PDF March 2021
    View all

    Monthly Current Affairs Quiz PDF

    • Current Affairs Quiz PDF September 2021
    • Current Affairs Quiz PDF August 2021
    • Current Affairs Quiz PDF July 2021
    • Current Affairs Quiz PDF June 2021
    • Current Affairs Quiz PDF May 2021
    • Current Affairs Quiz PDF April 2021
    • Current Affairs Quiz PDF March 2021
    View all